acamprosate has been researched along with Adverse Drug Event in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, D; Fang, H; Kelly, R; Liu, Z; Shi, Q; Tong, W | 1 |
| Bobashev, G; Coffey, CP; Edlund, MD; Jonas, DE; Kennedy, SM; Kuznacic, K; McPheeters, M; O'Connor, EA; Riley, S; Voisin, C | 1 |
| Ait-Daoud, N; Johnson, BA; Roache, JD | 1 |
| Hussar, DA | 1 |
1 review(s) available for acamprosate and Adverse Drug Event
| Article | Year |
|---|---|
Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Drug-Related Side Effects and Adverse Reactions; Humans; Naltrexone; Prospective Studies; Psychosocial Intervention; Quality of Life; United States | 2023 |
3 other study(ies) available for acamprosate and Adverse Drug Event
| Article | Year |
|---|---|
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Models, Biological; Predictive Value of Tests | 2011 |
The COMBINE SAFTEE: a structured instrument for collecting adverse events adapted for clinical studies in the alcoholism field.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Clinical Trials as Topic; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Guidelines as Topic; Health Personnel; Humans; Naltrexone; Narcotic Antagonists; Observer Variation; Surveys and Questionnaires; Taurine; Terminology as Topic | 2005 |
New drugs 06, part I.
Topics: Acamprosate; Adenine Nucleotides; Alcohol Deterrents; Amyloid; Analgesics, Non-Narcotic; Anti-HIV Agents; Antifungal Agents; Antineoplastic Agents; Aptamers, Nucleotide; Arabinonucleosides; Azabicyclo Compounds; Benzofurans; Clofarabine; Drug Approval; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Echinocandins; Exenatide; Fibroblast Growth Factor 7; Guanine; Humans; Hypoglycemic Agents; Islet Amyloid Polypeptide; Lipopeptides; Lipoproteins; Macular Degeneration; Micafungin; omega-Conotoxins; Patient Education as Topic; Peptides; Peptides, Cyclic; Piperazines; Pyrrolidines; Quinuclidines; Solifenacin Succinate; Stomatitis; Taurine; Tetrahydroisoquinolines; Urinary Incontinence; Venoms | 2006 |